Shattuck Labs To Host Investor Call And Webcast To Share Initial Clinical Trial Data From Phase 1A/B Dose-Expansion Cohorts In Frontline Higher-Risk Myelodysplastic Syndromes And TP53m Acute Myeloid Leukemia And Review Of Dose-Escalation Data From ASH
Portfolio Pulse from Benzinga Newsdesk
Shattuck Labs, Inc. (NASDAQ:STTK), a biotech company, announced an investor call to share initial clinical trial data from Phase 1A/B dose-expansion cohorts in HR-MDS and TP53m AML, and to review dose-escalation data from the 65th ASH Annual Meeting. The call is scheduled for December 13, 2023, at 8:00 a.m. ET and will be webcasted live on the company's Investor Relations page.
December 05, 2023 | 9:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Shattuck Labs will present initial clinical trial data which could significantly impact investor sentiment and the company's stock price, depending on the outcomes shared.
The announcement of clinical trial data is a critical event for biotech companies like Shattuck Labs. Positive data can lead to increased investor confidence and a potential rise in stock price, while negative data can have the opposite effect. Given that this is an initial data release, the impact is likely to be significant as it will shape investor expectations for the drug's future prospects.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100